Ivy Brain Tumor Center, SonALAsense and Insightec Announce the First Patient Dosed in First-in-Human Clinical Trial of Noninvasive Sonodynamic Therapy for the Treatment of Brain Cancer
The Ivy Center is pleased to announce the dosing of its first patient in a first-in-human Phase 0 clinical trial of sonodynamic therapy, a noninvasive drug-device combination developed by SonALAsense in collaboration with Insightec. This historic study aims to develop a nonsurgical treatment option for patients with recurrent glioblastoma and other high-grade gliomas.
In this Techonomy exclusive from Dr. Nader Sanai, director of the Ivy Brain Tumor Center, he discusses the "fail fast" adage associated with Silicon Valley and the implications this method could have on the healthcare industry specifically, in clinical trials.
First Patient Treated in Ivy Brain Tumor Center’s Phase 0 Clinical Trial of Pamiparib in Newly Diagnosed and Recurrent Glioblastoma
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the first patient has been treated in a Phase 0 clinical trial of pamiparib in newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM). This is the first Phase 0 clinical trial open to newly diagnosed glioblastoma patients.
BioSpace highlights the Ivy Brain Tumor Center's new drug-device combination treatment for glioblastoma. This article depicts the collaborative effort between the Ivy Center and SonALAsense and the promising GBM therapy on the horizon.
A promising non-invasive treatment to effectively and safely destroy deadly brain tumors is being tested on human patients for the first time ever at the Ivy Brain Tumor Center at the Barrow Neurological Institute in Phoenix.
Earlier this year, the Ivy Brain Tumor Center received FDA approval for a Phase 0 clinical trial to study a first-in-human drug-device combination that uses MRI-guided focused ultrasound in combination with aminolevulinic acid to selectively target and kill tumor cells. Peter Hofland of Onco'Zine covers the story in this article and what it could mean for the brain tumor community.
SonALAsense Pioneers Sonodynamic Therapy, a First-in-Class Noninvasive Therapy for Lethal Brain Cancers; Enters Into a Collaboration and License Agreement With Insightec and a Collaboration Agreement with Ivy Brain Tumor Center to Conduct the First-in-Man Clinical Trial for Recurrent Glioblastoma
The Ivy Brain Tumor Center is excited to collaborate with SonALAsense to conduct this first-in-human clinical trial that will rapidly assess a noninvasive drug-device combination therapy in patients with glioblastoma. This marks a major step forward for brain cancer patients as this novel approach has the potential to change the lives of hundreds of thousands of people impacted by this disease.
Ivy Brain Tumor Center Initiates Phase 0 Clinical Trial with BeiGene for Newly Diagnosed and Recurrent Glioblastoma
The Ivy Brain Tumor Center is conducting the first-ever Phase 0 clinical trial for newly diagnosed glioblastoma patients. This study will evaluate BeiGene’s pamiparib in combination with fractionated radiotherapy and will also be available to patients with recurrent glioblastoma.
In the eleventh annual edition of the International Brain Tumour Alliance (IBTA) magazine, Dr. Nader Sanai explains how the Ivy Brain Tumor Center's unique Phase 0 clinical trials program is providing tailored care for individuals struggling with brain cancer.
Navigating a brain tumor diagnosis can be overwhelming. That's where Jacki Garcia comes in. Jacki is a nurse navigator for Barrow patients with brain tumors, including those who undergo Phase 0 clinical trials at the Ivy Brain Tumor Center.